Short Interest in Aquestive Therapeutics, Inc. (NASDAQ:AQST) Decreases By 5.9%

Aquestive Therapeutics, Inc. (NASDAQ:AQST) was the recipient of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 11,090,000 shares, a drop of 5.9% from the January 15th total of 11,790,000 shares. Based on an average daily volume of 1,470,000 shares, the short-interest ratio is presently 7.5 days.

Aquestive Therapeutics Price Performance

Shares of NASDAQ AQST opened at $3.32 on Tuesday. The company has a market cap of $302.72 million, a PE ratio of -7.38 and a beta of 2.67. Aquestive Therapeutics has a 12 month low of $2.24 and a 12 month high of $6.23. The company has a 50-day simple moving average of $3.32 and a 200-day simple moving average of $4.19.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price for the company. Leerink Partners raised their target price on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 20th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $11.00.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of AQST. nVerses Capital LLC acquired a new stake in shares of Aquestive Therapeutics in the third quarter worth approximately $28,000. New York State Common Retirement Fund boosted its position in shares of Aquestive Therapeutics by 713.3% in the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after acquiring an additional 10,700 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Aquestive Therapeutics in the fourth quarter worth approximately $44,000. Two Sigma Advisers LP acquired a new stake in shares of Aquestive Therapeutics in the fourth quarter worth approximately $57,000. Finally, Harvey Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics in the third quarter worth approximately $88,000. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.